MedAI Verdict
All comparisons

PathAI AISight vs Tempus Digital Pathology

PathAI AISight and Tempus Digital Pathology both compete in pathology, but answer different questions. PathAI AISight is our pick for IMS + AI platform: Open IMS with AISight Dx + biopharma diagnostic services. Tempus Digital Pathology earns the Paige acquisition (Aug 2025) slot: Paige Predict 123-biomarker pan-cancer suite, now part of Tempus AI. The right choice depends on whether your priority is ims + ai platform or paige acquisition (aug 2025).

Category
Pathology
Tools compared
02
Reviewed
October 20, 2026
Editorial silo
/best-ai-pathology

The two contenders

Best open IMS + AI platform

PathAI AISight logo

PathAI AISight

by PathAI  ·  founded 2016

Cloud image management for digital pathology with AISight Dx, cleared for primary diagnosis, plus biopharma AI services.

Pricing
No public price. Billing period, trial and refund not stated.
Compliance
FDA 510(k)

Best after Paige acquisition (Aug 2025)

Digital pathology AI from Paige, now part of Tempus: Paige Prostate Detect (FDA De Novo, CE-IVDR) plus research-use suites.

Pricing
No public price on the Tempus pages.
Compliance
FDA De Novo (DEN200080) / FDA 510(k) (FullFocus viewer) / CE-IVDR

Side-by-side specifications

How PathAI AISight and Tempus Digital Pathology compare

Pricing, compliance, and integrations sourced from vendor documentation. Verified October 20, 2026.

SpecPathAI AISightTempus Digital Pathology
PricingNo public price. Billing period, trial and refund not stated.No public price on the Tempus pages.
Free tierNo / unverifiedNo / unverified
HIPAANo / unverifiedNo / unverified
SOC 2 Type IINo / unverifiedNo / unverified
EHR integrationsNot specifiedNot specified
Founded2016—
HQUSUS
Best forBest open IMS + AI platformBest after Paige acquisition (Aug 2025)

Scroll horizontally to see both columns.

Editorial verdict

When to pick each one

When to pick PathAI AISight

Best open IMS + AI platform

Open IMS with AISight Dx + biopharma diagnostic services.

  • Vendor-agnostic IMS appeals to mixed-vendor labs
  • Strong biopharma R&D revenue
Read the full PathAI AISight review

When to pick Tempus Digital Pathology

Best after Paige acquisition (Aug 2025)

Paige Predict 123-biomarker pan-cancer suite, now part of Tempus AI.

  • NASDAQ:TEM
  • Most clinical-validation depth
  • FDA + CE-IVDR cleared modules
Read the full Tempus Digital Pathology review

Wider context

Open the full pathology comparison

Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.

See all pathology

/best-ai-pathology